IDXX vs. IMMU, LNTH, NEOG, CLDX, QDEL, SYK, BSX, MDT, BDX, and EW
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Immunomedics (IMMU), Lantheus (LNTH), Neogen (NEOG), Celldex Therapeutics (CLDX), QuidelOrtho (QDEL), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector.
IDEXX Laboratories (NASDAQ:IDXX) and Immunomedics (NASDAQ:IMMU) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
In the previous week, IDEXX Laboratories had 21 more articles in the media than Immunomedics. MarketBeat recorded 21 mentions for IDEXX Laboratories and 0 mentions for Immunomedics. IDEXX Laboratories' average media sentiment score of 0.64 beat Immunomedics' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the media.
IDEXX Laboratories received 88 more outperform votes than Immunomedics when rated by MarketBeat users. Likewise, 72.47% of users gave IDEXX Laboratories an outperform vote while only 65.24% of users gave Immunomedics an outperform vote.
IDEXX Laboratories has higher revenue and earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories has a net margin of 23.26% compared to Immunomedics' net margin of 0.00%. IDEXX Laboratories' return on equity of 63.66% beat Immunomedics' return on equity.
IDEXX Laboratories has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Immunomedics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500.
87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 88.9% of Immunomedics shares are owned by institutional investors. 2.1% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 12.0% of Immunomedics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
IDEXX Laboratories presently has a consensus price target of $585.89, suggesting a potential upside of 24.73%. Given IDEXX Laboratories' higher probable upside, analysts clearly believe IDEXX Laboratories is more favorable than Immunomedics.
Summary
IDEXX Laboratories beats Immunomedics on 13 of the 17 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
Free IDXX Stock Alerts